MEBT/MEBO对糖尿病创面Smad1表达的影响的实验研究

Experimental study on the effect of MEBT/MEBO on wound healing and expression of Smad1 in diabetic wound

目的观察皮肤再生医疗技术[湿润暴露疗法(moist exposed burn therapy,MEBT)/湿润烧伤膏(moist exposed burn ointment,MEBO)]对糖尿病大鼠创面骨形成蛋白(BMP)/Smad信号通路中Smad1表达的影响,探讨MEBT/MEBO促进糖尿病创面愈合的机制。方法将90只Wistar大鼠随机分成对照组、模型组和MEBO组三个组,每组30只,对照组建立普通创面模型,模型组和MEBO组建立糖尿病创面模型,模型组和对照组采用生理盐水纱布湿敷换药,MEBO组采用MEBO干预创面,分别于治疗第1天、第5天、第11天,对比创面的愈合情况,取创面组织采用qRT-PCR技术检测Smad1的表达水平,免疫组化法检测大鼠创面中Smad1蛋白表达水平。结果(1)治疗第5天、第11天,三组大鼠创面愈合率对比,MEBO组>对照组>模型组(P<0.05);(2)治疗第1天、第5天、第11天,模型组Smad1 mRNA表达均低于对照组,MEBO组Smad1 mRNA表达高于对照组(P<0.05),三组的Smad1 mRNA表达在治疗第5天降低,治疗第11天达到高峰;(3)免疫组化显示Smad1蛋白表达在第5天达到高峰。结论MEBT/MEBO可促进糖尿病慢性创面愈合,其机制可能是通过调控Smad1表达和BMP/Smad信号通路。

Objective To observe the skin regeneration medical technique(moist exposed burn therapy[MEBT]/moist exposed burn ointment[MEBO]) on the expression of Smad1 in wound bone morphogenetic protein(BMP)/Smad signaling pathway in diabetic rats, so as to explore the mechanism of MEBT/MEBO in promoting diabetic wound healing. Methods 90 Wistar rats were randomly divided into 3 groups: control group, model group and MEBO group, with 30 rats in each group. Normal wound model was established in the control group, and diabetic wound models were established in the model group and the MEBO group.The model group and the control group were treated with wet dressing with saline gauze, while the MEBO group were treated with MEBO to intervene the wound. And then, the wound healing was compared on the 1 st, 5 th and 11 th day of treatment, respectively. Wound tissues were taken, and the expression level of Smad1 was detected by qRT-PCR, and Smad1 protein expression level was detected by immunohistochemistry. Results(1) On the 5 th and 11 th day of treatment, the wound healing rates of the 3 groups were compared, which showed that MEBO group>control group>model group(P<0.05);(2) On the 1 st, 5 th and 11 th day of treatment, the expression levels of Smad1 and mRNA in the model group were lower than those in the control group, and the expression levels of Smad1 and mRNA in the MEBO group were higher than those in the control group(P<0.05). The expression levels of Smad1 and mRNA in the three groups decreased on the 5 th day of treatment and reached the peak on the 11 th day of treatment;(3)Immunohistochemistry showed that the protein expression levels of Smad1 reached the peak on the 5 th day of treatment. Conclusion MEBT/MEBO can promote the healing of chronic wound in diabetes mellitus, and the mechanism may be through regulating Smad1 expression and BMP/Smad signaling pathway.